Insmed receives fda breakthrough therapy designation for brensocatib in patients with non-cystic fibrosis bronchiectasis (ncfbe)

Bridgewater, n.j., june 8, 2020 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the u.s. food and drug administration (fda) has granted breakthrough...
INSM Ratings Summary
INSM Quant Ranking